Let’s look at the key reasons that are pushing CRISPR Therapeutics AG (CRSP) to new highs

A new trading day began on Monday, with CRISPR Therapeutics AG (NASDAQ: CRSP) stock price down -8.00% from the previous day of trading, before settling in for the closing price of $36.99. CRSP’s price has ranged from $36.52 to $68.39 over the past 52 weeks.

During the last 5-year period, the sales growth of Healthcare Sector giant was 31550.17%. Meanwhile, its annual earnings per share averaged -10.94%. With a float of $82.06 million, this company’s outstanding shares have now reached $85.74 million.

Let’s determine the extent of company efficiency that accounts for 393 employees. In terms of profitability, gross margin is -227.47%, operating margin of -1273.97%, and the pretax margin is -990.27%.

CRISPR Therapeutics AG (CRSP) Breakdown of a Key Holders of the stock

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CRISPR Therapeutics AG is 4.33%, while institutional ownership is 69.35%. The most recent insider transaction that took place on Mar 21 ’25, was worth 413,578. In this transaction Chief Executive Officer of this company sold 10,031 shares at a rate of $41.23, taking the stock ownership to the 195,085 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Operating Officer sold 1,714 for $41.23, making the entire transaction worth $70,668. This insider now owns 10,544 shares in total.

CRISPR Therapeutics AG (CRSP) Recent Fiscal highlights

Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -10.94% per share during the next fiscal year.

CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators

Here are CRISPR Therapeutics AG’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 22.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 78.23.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.36, a number that is poised to hit -1.23 in the next quarter and is forecasted to reach -4.05 in one year’s time.

Technical Analysis of CRISPR Therapeutics AG (CRSP)

Looking closely at CRISPR Therapeutics AG (NASDAQ: CRSP), its last 5-days average volume was 2.26 million, which is a jump from its year-to-date volume of 2.14 million. As of the previous 9 days, the stock’s Stochastic %D was 5.14%. Additionally, its Average True Range was 2.29.

During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 4.10%, which indicates a significant decrease from 9.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.78% in the past 14 days, which was lower than the 58.13% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $42.78, while its 200-day Moving Average is $47.62. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $35.53. Second resistance stands at $37.04. The third major resistance level sits at $38.32. If the price goes on to break the first support level at $32.74, it is likely to go to the next support level at $31.46. Now, if the price goes above the second support level, the third support stands at $29.95.

CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats

With a market capitalization of 2.92 billion, the company has a total of 85,774K Shares Outstanding. Currently, annual sales are 37,310 K while annual income is -366,250 K. The company’s previous quarter sales were 35,690 K while its latest quarter income was -37,310 K.